GIPR and type 2 diabetes mellitus: The use of glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor (GIPR/GLP-1R) agonists, such as tirzepatide, has been shown to improve glucose and lipid metabolism in T2DM patients, as measured by indirect calorimetry (40, 41).